AstraZeneca settles with Ranbaxy to stave off generic Nexium launch

Share this article:
AstraZeneca settled a patent dispute with Ranbaxy, which had threatened an “at risk” early generic launch against AstraZeneca's $5.5 billion drug Nexium. The settlement allows Ranbaxy to launch a generic version of the drug in 2014 – three years earlier than the currently listed patent expiration date. Ranbaxy will also manufacture the active ingredient in the drug, esomeprazole magnesium, starting in May 2009, and Ranbaxy becomes the US distributor for authorized generic versions of Plendil and 40 mg Prilosec. 

Merck, which collects royalties on the drug, was also a party to the settlement. 

The move mitigates a serious near-term threat to AstraZeneca and, to a lesser degree, Merck. But AstraZeneca still faces a “substantial generic cliff” over the next decade, said Bernstein analyst Tim Anderson, who flagged the risk of an early generic launch against Nexium in February.

Nexium is AstraZeneca's top-selling drug, accounting for a tenth of the company's revenues, as well as one of the most visible and best-supported brands in consumer advertising.  

Patent infringement litigation between AstraZeneca and other generics-makers, including Teva/IVAX and Dr. Reddy's, is ongoing.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...